LGVN stock news · Longeveron Inc.

Stories about Longeveron Inc. (LGVN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for LGVN

Follow Longeveron Inc. (LGVN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Nov 12, 2026, 5:14 PM ET · Trial
Longeveron shared its third-quarter results and plans to meet with the FDA about its HLHS program.
Bad for LGVN
Longeveron’s trial for a rare heart defect missed its main goal, and the company is reviewing funding or sale options. This weighs against it despite one favorable result.
Sep 23, 2026, 4:04 PM ET · Market
Longeveron Inc. shares news about its trial results for a heart treatment.
Bad for LGVN
Longeveron reported its Phase 2b trial failed its main measure, a result we read as negative for Longeveron.
Sep 18, 2026, 2:27 PM ET · Market
On Friday, 12 health care stocks changed a lot in price, with IM Cannabis jumping 246%.
Bad for LGVN
Longeveron stock fell 12.74% to $2.37. The intraday decline lowers the market value of its shares and reflects selling pressure today.
Sep 17, 2026, 1:15 PM ET · Market
On Thursday, 12 health care stocks changed a lot, with Aethlon Medical jumping 330.8% and Longeveron dropping 57.3%.
Neutral
Longeveron fell in the session, but the report only notes the price move and market cap, so this single-day drop does not change the business reading.